Kimberly Schaff

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.

Alden A. Moccia, Kimberly Schaff, Paul Hoskins et al. · Blood · 2009 · 47 citations

Medicine, Oncology, Pharmacology +13

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Alden A. Moccia, Kimberly Schaff, Ciara L. Freeman et al. · Blood Advances · 2021 · 44 citations · Full text

Medicine, Oncology, Chemotherapy +15

Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix

Erica S. Tsang, Yarrow J. McConnell, David F. Schaeffer et al. · Annals of Surgical Oncology · 2018 · 35 citations

Medicine, Oncology, Surgery +11

Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis

Mário L de Lemos, Isabell Kang, Kimberly Schaff · Journal of Oncology Pharmacy Practice · 2018 · 23 citations

Medicine, Clinical Sciences, Oncology +9

A real-world data approach to determine the optimal dosing strategy for pembrolizumab

Ashley Jang, Lynne Nakashima, Tonya Ng et al. · Journal of Oncology Pharmacy Practice · 2020 · 17 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17